Sichenzia Ross Ference LLP Represents Equillium, Inc. in a $30 Million Registered Direct Offering

Press Release – New York, NY – February 8, 2021 – Sichenzia Ross Ference LLP announced today that it has represented Equillium, Inc. (NASDAQ:EQ) in a registered direct offering with life science institutional investment funds managed by Decheng Capital that purchased 4,285,710 units (the “Units”) from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit is $7.00, priced above the market under Nasdaq rules. The warrants will have an exercise price of $14.00 per share, will be immediately exercisable, and will expire on the earlier of (i) the fifth anniversary of issuance, or (ii) the 15th calendar date following the date on which Equillium closes a financing raising a minimum of $25 million at a price per share of no less than $25.00.

The Units were sold by the Company pursuant to a “shelf” registration statement on Form S-3 (333-234683) filed with the SEC.

Equillium is a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders

The Sichenzia Ross Ference LLP team was led by partners Marc J. Ross and James M. Turner and associate Jacob Tabman.

Author
Recent Posts

Sichenzia Ross Ference Carmel LLP

Sichenzia Ross Ference Carmel LLP is a full service law firm with a nationally recognized corporate, securities and litigation practice that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation department specializes in defending companies and individuals against all types of securities cases, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations. The litigation team has also brought defamation lawsuits against companies and individuals related to market manipulation. Additionally, it represents individuals and companies in investigations by the Securities and Exchange Commission (SEC) and other regulatory bodies. The litigation team has a robust practice representing brokers and broker-dealers in arbitrations before the Financial Industry Regulatory Authority (FINRA). These arbitrations typically involve claims of unsuitability, churning, unauthorized trading and other allegations of broker misconduct. Finally, SRF has a burgeoning expungement practice, where it represents brokers seeking to have negative and harmful customer complaints removed from their industry records. The firm complements its core practice areas with an established commercial real estate and trusts and estates practice.

Visit SRFC's LinkedIn page

Latest posts by Sichenzia Ross Ference Carmel LLP (see all)

Sichenzia Ross Ference LLP Represents Equillium, Inc. in a $30 Million Registered Direct Offering

Related Posts